Sparrow Pharmaceuticals is a targeted cardiometabolic therapeutics company developing clofutriben, a once-daily oral HSD-1 inhibitor, for patients with type 2 diabetes (T2D) and elevated cortisol.
© Copyright RiverVest® All Rights Reserved.
